Is WHO International Standard for Anti-SARS-CoV-2 Immunoglobulin Clinically Useful?
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection | Nature Medicine
Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection - eBioMedicine
Is WHO International Standard for Anti-SARS-CoV-2 Immunoglobulin Clinically Useful?
Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection | Nature Medicine
Diagnostics | Free Full-Text | Quantitative SARS-CoV-2 Spike Antibody Response in COVID-19 Patients Using Three Fully Automated Immunoassays and a Surrogate Virus Neutralization Test
Frontiers | The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients
Frontiers | IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers
The comparability of Anti-Spike SARS-CoV-2 antibody tests is time-dependent: a prospective observational study | medRxiv
Frontiers | The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients
Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article - ScienceDirect
Vaccines | Free Full-Text | Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
Improvements and limits of anti SARS-CoV-2 antibodies assays by WHO (NIBSC 20/136) standardization
Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection - eBioMedicine
Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection - eBioMedicine
Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine
Vaccines | Free Full-Text | Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article - ScienceDirect
Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection - eBioMedicine
Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays | Microbiology Spectrum
Validation and performance of a multiplex serology assay to quantify antibody responses following SARS‐CoV‐2 infection or vaccination - Wilkins - 2022 - Clinical & Translational Immunology - Wiley Online Library
Validation and performance of a multiplex serology assay to quantify antibody responses following SARS‐CoV‐2 infection or vaccination - Wilkins - 2022 - Clinical & Translational Immunology - Wiley Online Library
